Analyst Conference Summaries

Biotechnology Investor Aids

Mylan, Inc.
MYL

Note: I sold my Mylan stock on September 3, 2019. Reluctantly, because I believe it is very undervalued. But with the merger ahead, I decided I might as well close the position out and consider new investments.

conference date: July 29, 2019 @ 5:30 AM Pacific Time (merger conference)

Mylan Grinding Towards Greatness by William Meyers [September 4, 2018 @ Seeking Alpha]

Mylan's Concerns: Debt and Capital Allocation [January 25, 2017 @ Seeking Alpha]

What is $6 in 2017 EPS Worth for Mylan? [February 17, 2016]
Mylan note re Biosimilars [March 11, 2015]

Analyst Call Notes by William P. Meyers
2019
Mylan
Q1 2019
Mylan
Q2 2019
   
May 7, 2019 July 29, 2019    
2018
Mylan
Q4 2018
May 9, 2018
August 8, 2018
Nov. 5, 2018
Feb. 26, 2019
2017
May 10, 2017
August 9, 2017
Nov. 6, 2017
Feb. 28, 2018
2016
05/03/2016
08/09/2016
11/09/2016
03/01/2017
2015
05/05/2015
08/06/2015
10/30/2015
02/10/2016
2014
05/01/2014
08/07/2014
10/30/2014
 03/02/2015
2013
not available

08/01/2013
10/31/2013 
 02/27/2014

Mylan is Deeply Undervalued [August 27, 2014]

Mylan Pursues Global Generics Dominance Strategy [September 6, 2013]

Mylan (MYL) is a manufacturer of generic drugs and therapies.

Mylan web site
Mylan investor relations page

I took an initial position in Mylan on March 20, 2014

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes, not financial advice, and may be the basis of my Seeking Alpha articles.

Copyright 2019 William P. Meyers